PT - JOURNAL ARTICLE AU - Markus Reindl AU - Kathrin Schanda AU - Mark Woodhall AU - Fiona Tea AU - Sudarshini Ramanathan AU - Jessica Sagen AU - James P. Fryer AU - John Mills AU - Bianca Teegen AU - Swantje Mindorf AU - Nora Ritter AU - Ulrike Krummrei AU - Winfried Stöcker AU - Juliane Eggert AU - Eoin P. Flanagan AU - Melanie Ramberger AU - Harald Hegen AU - Kevin Rostasy AU - Thomas Berger AU - Maria Isabel Leite AU - Jacqueline Palace AU - Sarosh R. Irani AU - Russell C. Dale AU - Christian Probst AU - Monika Probst AU - Fabienne Brilot AU - Sean J. Pittock AU - Patrick Waters TI - International multicenter examination of MOG antibody assays AID - 10.1212/NXI.0000000000000674 DP - 2020 Mar 05 TA - Neurology - Neuroimmunology Neuroinflammation PG - e674 VI - 7 IP - 2 4099 - http://nn.neurology.org/content/7/2/e674.short 4100 - http://nn.neurology.org/content/7/2/e674.full SO - Neurol Neuroimmunol Neuroinflamm2020 Mar 05; 7 AB - Objective To compare the reproducibility of 11 antibody assays for immunoglobulin (Ig) G and IgM myelin oligodendrocyte glycoprotein antibodies (MOG-IgG and MOG-IgM) from 5 international centers.Methods The following samples were analyzed: MOG-IgG clearly positive sera (n = 39), MOG-IgG low positive sera (n = 39), borderline negative sera (n = 13), clearly negative sera (n = 40), and healthy blood donors (n = 30). As technical controls, 18 replicates (9 MOG-IgG positive and 9 negative) were included. All samples and controls were recoded, aliquoted, and distributed to the 5 testing centers, which performed the following antibody assays: 5 live and 1 fixed immunofluorescence cell-based assays (CBA-IF, 5 MOG-IgG, and 1 MOG-IgM), 3 live flow cytometry cell-based assays (CBA-FACS, all MOG-IgG), and 2 ELISAs (both MOG-IgG).Results We found excellent agreement (96%) between the live CBAs for MOG-IgG for samples previously identified as clearly positive or negative from 4 different national testing centers. The agreement was lower with fixed CBA-IF (90%), and the ELISA showed no concordance with CBAs for detection of human MOG-IgG. All CBAs showed excellent interassay reproducibility. The agreement of MOG-IgG CBAs for borderline negative (77%) and particularly low positive (33%) samples was less good. Finally, most samples from healthy blood donors (97%) were negative for MOG-IgG in all CBAs.Conclusions Live MOG-IgG CBAs showed excellent agreement for high positive and negative samples at 3 international testing centers. Low positive samples were more frequently discordant than in a similar comparison of aquaporin-4 antibody assays. Further research is needed to improve international standardization for clinical care.ADEM=acute disseminated encephalomyelitis; AQP4=aquaporin-4; CBA=cell-based assay; FACS=fluorescence-activated cell sorting; IF=immunofluorescence; IfQ=Institute for Quality Assurance; Ig=immunoglobulin; MOG=myelin oligodendrocyte glycoprotein; NMOSD=neuromyelitis optica spectrum disorder